10
Dec
2024

GENOVIOR BIOTECH CORPORATION

Exhibitor at CPHI Middle East 2024 stand 3.C3
About Us

Genovior is a dedicated CMO/CDMO, focusing on providing clients excellent, efficient, one stop services and solutions, from clinical trials (IND/NDA) to commercialization.

Our services include:
1. Process Development
2. Formulation Development
3. Analytical Development
4. Small Scale Biologics / Injectable Production
5. Commercial Scale Injectable Production
6. Dedicated Oncology Production (API / Injectables)
7. Regulatory Affairs

Generic/Peptide/Biosimilar projects available for out-licensing
Oncology-Azacitidine, Bortezomib, Pemetrexed, Fulvestrant
Peptide-Glucagon, Teriparatide, Octreotide, Terlipressin
Biosimilar-Liraglutide, Ranibizumab, Denosumab

Others-Levetiracetam, Palonosetron, Valproate

  • TW
  • 2016
    On CPHI since
  • 1
    Certificates
  • 100 - 249
    Employees
Company types
CMO/CDMO
Primary activities
Contract Manufacturer
Contact info
  • 4F No. 50-8 Keyan RD , Zhunan Township , 35053, Miaoll County , Taiwan, China
Event information
CPHI Middle East 2024
  • 10 Dec 2024 - 12 Dec 2024
  • Riyadh Front Exhibition & Convention Center Riyadh, Saudi Arabia
  • Visit us at stand 3.C3

Products Featured at CPHI Middle East 2024

  • Semaglutide (GLP-1 Drug)

    Product Semaglutide (GLP-1 Drug)

    API < USD 500 per gram, COA available Finished product
  • CDMO Services

    Product CDMO Services

    Genovior is a dedicated CMO/CDMO, focusing on providing clients excellent, efficient, one stop services and solutions, from clinical trials (IND/NDA) to commercialization.

    Our services include:

    1. Process Development
    2. Formulation Development
    3. Analytical Development
    ...
  • CDMO Services - API

    Product CDMO Services - API

    small moleculepeptide
    biologics
  • CDMO Services - FDF drugs

    Product CDMO Services - FDF drugs

    VialsPrefilled Syringe
    Injection Pen 
  • Genovior Products - API

    Product Genovior Products - API

    • Azacitidine (Oncology) • Bortezomib (Oncology) • Fulvestrant (Oncology) • Pemetrexed (Oncology) • Ponatinib (Oncology) • Glucagon (Endocrinology) • Octreotide (Endocrinology) • Teriparatide (Osteoporosis)
  • Genovior Products - FDF Drugs List 1

    Product Genovior Products - FDF Drugs List 1

    Azacitidine inj

    Bortezomib inj

    Docetaxel inj

    Doxorubicin inj

    Epirubicin inj

    Fulvestrant inj

    Gemcitabine inj

    ...
  • Genovior Products - FDF Drugs List 2

    Product Genovior Products - FDF Drugs List 2

    Acyclovir inj

    Colistin inj

    Ganciclovir inj

    Teicoplanin inj

    Vancomycin inj

    Levetiracetam inj

    Valproate inj

    ...
  • Interview by Newsweek, time to talk

    Product Interview by Newsweek, time to talk

    Interviewee:Dr. Steve J.P. Hsu (President of Genovior Biotech)

GENOVIOR BIOTECH CORPORATION Resources (5)

  • Video COMPANY PRESENTATION

    Genovior is a dedicated CMO/CDMO, focusing on providing clients excellent, efficient, one stop services and solutions, from clinical trials (IND/NDA) to commercialization.

    Our services include:
    1. Process Development
    2. Formulation Development
    3. Analytical Development
    4. Small Scale Biologics / Injectable Production
    5. Commercial Scale Injectable Production

    6. Dedicated Oncology Production (API / Injectables)
    7. Regulatory Affairs

    Generic/Peptide/Biosimilar projects available for out-licensing
    Oncology-Azacitidine, Bortezomib, Pemetrexed, Fulvestrant
    Peptide-Glucagon, Teriparatide, Octreotide, Terlipressin
    Biosimilar-Liraglutide, Ranibizumab, Denosumab
    Others-Levetiracetam, Palonosetron, Valproate

  • Brochure Interview by Newsweek, Time to Talk

    Interviewee:Dr. Steve J. P. Hsu (President of Genovior Biotech)